Maximising opportunities

We work closely with entrepreneurs and investors at the forefront of the global healthcare revolution. Our in-depth sector knowledge, combined with our technical capability, enables us to help corporates and investors capitalise on the enormous opportunities across the sector as they seek to consolidate and grow their market positions.

The ageing population, technological change, and increased demand for healthcare products and services, all create great opportunities in the health and social care, medical devices, life sciences, bioscience and pharmaceutical markets. Our job is to help our clients maximise those opportunities.

< >

Our latest transactions

Clearwater has been very professional in leading the process involving candidates from all over the world.

Luc Bertholat, Partner, Naxicap Partners

Our Healthcare Team

The team were quickly able to identify the right partner for us and used their excellent relationship with the buyer to help negotiate a transaction that met our objectives.
Dan Smart, CEO, Proclinical

With in-depth knowledge and technical capability, our healthcare team has a great track record of delivering tailored solutions.

See our team

Over 80

deals advised upon

in the last 5 years


deal value

over the last 5 years

Over 40%

deals involving PE

in the last 5 years


  • Contract Commercialisation Market (CCOs)

    CCOs offer a broad range of commercialisation services to their customers, typically focussed on preparing new products for launch and maximising sales post approval.

    Read more
  • Contract Development and Manufacturing Market (CDMOs)

    As innovator pipelines have deepened and the complexities of developing and manufacturing more recent generations of pharma (including biologics) have increased, the need to simplify manufacturing operations and reduce operating expenditure has led to the emergence of the CDMO industry.

    Read more
  • Contract Research Organisations (CROs)

    CROs are constantly expanding their addressable markets by broadening their service offerings, capturing an increasing share of pharma R&D expenditure. Investment in technology and big data will continue to play an important role in the expansion of the CRO sub-sector.

    Read more